You are here

CAR-T

Italian gene therapy player draws new investor from China for its answer to CAR-T relapses

Italian gene therapy player draws new investor from China for its answer to CAR-T relapses

Endpoints

Genenta Science

clinical trials

Multiple Myeloma

Flag link:

Trying to turn 'natural killers' against cancer, Nkarta raises $114 million

Trying to turn 'natural killers' against cancer, Nkarta raises $114 million

Bizjournals

Nkarta Therapeutics

natural killer cells

Flag link:

Achilles raises £100M for personalized T cell solid tumor trials

Achilles raises £100M for personalized T cell solid tumor trials

Fierce Biotech

Achilles Therapeutics

Flag link:

Autolus drags on Arix after weak period for CAR-T player

Autolus drags on Arix after weak period for CAR-T player

Fierce Biotech

Autolus Therapeutics

Arix Bioscience

Flag link:

Revealing the true value of new cancer drugs to payers

Revealing the true value of new cancer drugs to payers

Pharmaforum

Flag link:

Autolus delays multiple CAR-T clinical programs

Autolus delays multiple CAR-T clinical programs

Fierce Biotech

Flag link:

CMS to cover CAR-T therapy nationwide

CMS to cover CAR-T therapy nationwide

Beckers Hospital Review

Flag link:

A personalized CAR-T to attack every solid tumor? Pact Pharma has a plan

A personalized CAR-T to attack every solid tumor? Pact Pharma has a plan

Fierce Biotech

personalized medicine

Flag link:

Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

Endpoints

Precision Biosciences

drug manufacturing

Flag link:

Biotech building facility to make genome-edited, off-the-shelf CAR-T therapies

Biotech building facility to make genome-edited, off-the-shelf CAR-T therapies

Fierce Pharma

Precision Biosciences

drug manufacturing

Flag link:

Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

BioSpace

Kyoto University

Flag link:

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Fierce Pharma

Gilead Sciences

Flag link:

Boosting CAR-T to treat solid tumors with a vaccine

Boosting CAR-T to treat solid tumors with a vaccine

Fierce Biotech

cancer vaccines

Flag link:

Are Natural Killer Cells the Next Big Thing in Immunotherapy?

Are Natural Killer Cells the Next Big Thing in Immunotherapy?

Motley Fool

NK immunotherapies

Flag link:

Pressing the pause button on CAR-T cells with Bristol-Myers’ leukemia drug

Pressing the pause button on CAR-T cells with Bristol-Myers’ leukemia drug

Fierce Biotech

Bristol-Myers Squibb

cytokine release syndrome

Flag link:

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

BioCentury

Flag link:

ASCO 2019 day two

ASCO 2019 day two

Pharmaforum

Gilead Sciences

Flag link:

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Endpoints

Gilead Sciences

Flag link:

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Endpoints

Flag link:

Gilead's first move under new chief is to untether Kite

Gilead's first move under new chief is to untether Kite

Biopharma Dive

Gilead Sciences

Flag link:

Pages